Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Pre-absorption physicochemical compatibility assessment of 8-drug metabolic cocktail.

Tye CK, Wang Z, Dockens RC, Vakkalagadda B, Wang C, Zhang Y, Su CC, Hageman MJ.

Int J Pharm. 2016 Dec 5;514(2):364-373. doi: 10.1016/j.ijpharm.2016.06.028. Epub 2016 Jun 9.

PMID:
27291974
2.

Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.

Albright CF, Dockens RC, Meredith JE Jr, Olson RE, Slemmon R, Lentz KA, Wang JS, Denton RR, Pilcher G, Rhyne PW, Raybon JJ, Barten DM, Burton C, Toyn JH, Sankaranarayanan S, Polson C, Guss V, White R, Simutis F, Sanderson T, Gillman KW, Starrett JE Jr, Bronson J, Sverdlov O, Huang SP, Castaneda L, Feldman H, Coric V, Zaczek R, Macor JE, Houston J, Berman RM, Tong G.

J Pharmacol Exp Ther. 2013 Mar;344(3):686-95. doi: 10.1124/jpet.112.199356. Epub 2012 Dec 28.

PMID:
23275065
3.

Development of oral extended release formulations of 6-hydroxybuspirone.

Nicholson SJ, Timmins P, Dockens RC, Connor A, Croop R, Ferrie P, Zeng J, Dennis AB, Wilding I.

Biopharm Drug Dispos. 2012 Dec;33(9):522-35. doi: 10.1002/bdd.1819. Epub 2012 Nov 12.

PMID:
23065950
4.

Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men.

Tong G, Castaneda L, Wang JS, Sverdlov O, Huang SP, Slemmon R, Gu H, Wong O, Li H, Berman RM, Smith C, Albright C, Dockens RC.

Clin Drug Investig. 2012 Nov;32(11):761-9. doi: 10.1007/s40261-012-0006-4.

PMID:
23018285
5.

Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.

Tong G, Wang JS, Sverdlov O, Huang SP, Slemmon R, Croop R, Castaneda L, Gu H, Wong O, Li H, Berman RM, Smith C, Albright CF, Dockens RC.

Clin Ther. 2012 Mar;34(3):654-67. doi: 10.1016/j.clinthera.2012.01.022. Epub 2012 Feb 28.

PMID:
22381714
6.

In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.

Zhou L, Dockens RC, Liu-Kreyche P, Grossman SJ, Iyer RA.

Drug Metab Dispos. 2012 Jun;40(6):1093-103. doi: 10.1124/dmd.111.043596. Epub 2012 Mar 1.

PMID:
22381334
7.

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.

Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG.

Depress Anxiety. 2010 May;27(5):417-25. doi: 10.1002/da.20695.

PMID:
20455246
8.

Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans.

Zhu M, Whigan DB, Chang SY, Dockens RC.

Drug Metab Dispos. 2008 Jan;36(1):24-35. Epub 2007 Oct 1.

PMID:
17908924
9.
10.

6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats.

Wong H, Dockens RC, Pajor L, Yeola S, Grace JE Jr, Stark AD, Taub RA, Yocca FD, Zaczek RC, Li YW.

Drug Metab Dispos. 2007 Aug;35(8):1387-92. Epub 2007 May 9.

PMID:
17494642
11.

Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range.

Dockens RC, Salazar DE, Fulmor IE, Wehling M, Arnold ME, Croop R.

J Clin Pharmacol. 2006 Nov;46(11):1308-12.

PMID:
17050795
12.

Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction.

Kostis JB, Dockens RC, Thadani U, Bethala V, Pepine C, Leimbach W, Vachharajani N, Raymond RH, Stouffer BC, Tay LK, Shyu WC, Liao WC.

Clin Pharmacokinet. 2002;41(6):445-52.

PMID:
12074692
13.

Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa.

Frackiewicz EJ, Jhee SS, Shiovitz TM, Webster J, Topham C, Dockens RC, Whigan D, Salazar DE, Cutler NR.

Ann Pharmacother. 2002 Feb;36(2):225-30.

PMID:
11847938
14.

Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans.

Dockens RC, Santone KS, Mitroka JG, Morrison RA, Jemal M, Greene DS, Barbhaiya RH.

Drug Metab Dispos. 2000 Aug;28(8):973-80.

PMID:
10901709
15.

The lack effect of food on the bioavailability of nefazodone tablets.

Dockens RC, Greene DS, Barbhaiya RH.

Biopharm Drug Dispos. 1996 Mar;17(2):135-43.

PMID:
8907720
16.
17.

Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam.

Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH.

J Clin Psychopharmacol. 1995 Dec;15(6):409-16.

PMID:
8748429
18.

Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam.

Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH.

J Clin Psychopharmacol. 1995 Dec;15(6):399-408.

PMID:
8748428
20.

Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects.

Salazar DE, Dockens RC, Milbrath RL, Raymond RH, Fulmor IE, Chaikin PC, Uderman HD.

J Clin Pharmacol. 1995 Jul;35(7):730-8.

PMID:
7560254
21.
22.

Anticonvulsant activity of some 4-aminobenzamides.

Clark CR, Wells MJ, Sansom RT, Norris GN, Dockens RC, Ravis WR.

J Med Chem. 1984 Jun;27(6):779-82.

PMID:
6737420

Supplemental Content

Loading ...
Support Center